Li Dean Y
- SEC CIK
- 0001837016
In the past year, 2 open-market sale filings worth $2.99M and no purchases.
Current role at each company
- RXRX Recursion Pharmaceuticals, Inc.Directoras of Jul 2, 2026
- MRK Merck & Co., Inc.Executive VP & President, MRLas of May 7, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $2.99M
- 2 filings
- Net
- −$2.99M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Li Dean Y as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MRK Merck & Co., Inc.
Executive VP & President, MRL3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 (view filing) | Feb 10 | Same day | Li Dean YExecutive VP & President, MRL | SSale | −10.2K | $117.52 | −$1.20M | −10.0%92.0K after | |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Li Dean YExecutive VP & President, MRL | SSale | −15.1K | $118.77 | −$1.79M | −12.9%102.3K after | |
| Feb 12, 2024 (view filing) | Feb 9 | 3 days | Li Dean YExecutive VP & President, MRL | SSale | −14.7K | $125.50 | −$1.85M | −24.1%46.2K after |
RXRX Recursion Pharmaceuticals, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 11, 2024 (view filing) | Jan 9 | 2 days | Li Dean YDirector | SSaleClass A Common Stock | −29.0K | $13.66 | −$396.2K | −6.4%421.0K after | 2 lots10b5-1 |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Li Dean YDirector | SSaleClass A Common Stock | −15.9K | $20.48 | −$325.6K | −1.2%1.31M after | 2 lots |
| Dec 9, 2021 (view filing) | Nov 17-19 | 22 days | Li Dean YDirector | SSaleClass A Common Stock | −19.1K | $20.15 | −$384.9K | −1.4%1.33M after | Amended2 lots |